AtriCure has announced the first use of the newest AtriClip device for minimally invasive concomitant procedures, the AtriClip PRO-Mini left atrial appendage (LAA) exclusion system.
The AtriClip PRO-Mini device received US Food and Drug Administration (FDA) 510(k) clearance earlier this year and builds upon the technology of the widely used AtriClip platform. The device is preloaded with the smallest surgical LAA Management implant available in the market, according to AtriCure, stating that the implant is 60% smaller than the next lowest profile AtriClip device.
The significant size reduction is intended to provide surgeons with enhanced visualisation, ensuring precise and secure exclusion of the LAA during minimally invasive procedures.
“The AtriClip PRO-Mini device represents a leap forward in surgical LAA management,” said Michael Carrel, president and chief executive officer at AtriCure. “This device demonstrates our unwavering commitment to innovating best-in-class surgical solutions and builds upon our 20+ year legacy in surgical appendage management. This technology is empowering surgeons with improved visualization and precision.”
“The AtriClip PRO-Mini device immediately impressed me with its significantly smaller profile,” said Ahmed Romeya, cardiovascular surgeon at Midwest Heart and Vascular Specialists (Overland Park, USA). “It maintained the parallel closure and uniform pressure necessary for effective left atrial appendage exclusion. The enhanced visualisation offered by the AtriClip PRO-Mini device will undoubtedly increase surgeon confidence during these procedures.”
